Pennsylvania is currently home to 3474 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
NCT05552261
Recruiting
The primary objectives are to evaluate the long-term safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in Stage 1 Neurotrophic Keratitis (NK) patients who enrolled in the DEFENDO Study.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2023
Locations: Scheie Eye Institute, Philadelphia, Pennsylvania
Conditions: Neurotrophic Keratitis
Register for Updates
Use of an Intrauterine Manipulator and Its Correlation With Positive Peritoneal Cytology in Early Stage Endometrial Cancers
NCT04570553
Recruiting
This study aims to answer whether use of a Vcare® intrauterine manipulator leads to an increased incidence of positive peritoneal cytology in patients undergoing surgical management of early stage (FIGO stage I/II) endometrial cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/14/2023
Locations: Wellspan Health, York, Pennsylvania
Conditions: Endometrial Cancer
Register for Updates
Detection of Genetic Markers of Lung Cancer
NCT00280202
Recruiting
The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/08/2023
Locations: Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Lung Cancer
Register for Updates
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
NCT03669614
Recruiting
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmaco... Read More
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
03/07/2023
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Cystic Fibrosis
Register for Updates
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
NCT02235857
Recruiting
Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipid... Read More
Gender:
All
Ages:
21 years and below
Trial Updated:
03/07/2023
Locations: St. Christopher's Hospital for Children, Philadelphia, Pennsylvania
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
NCT04155710
Recruiting
This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is relapsing during treatment with ibrutinib or acalabrutinib.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/06/2023
Locations: Allegheny Health, Pittsburgh, Pennsylvania
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Phenotyping Genetic Risk for Type 2 Diabetes
NCT04024631
Recruiting
This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.
Gender:
All
Ages:
Between 10 years and 70 years
Trial Updated:
03/03/2023
Locations: Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Diabetes Mellitus, Type 2, Genetics
Register for Updates
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT03412643
Recruiting
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: Wellspan Health - York Cancer Center, York, Pennsylvania
Conditions: HER2-negative Breast Cancer
Register for Updates
Non-invasive Vagal Neurostimulation (nVNS) for Traumatic Brain Injury (TBI)-Induced Acute Respiratory Distress
NCT04935697
Recruiting
This is a prospective, randomized, two-arm, controlled 30-day investigational pilot trial using the gammaCore Sapphire S non-invasive vagus nerve stimulation (nVNS) device + standard of care (SOC) in newly-hospitalized patients with mild-to-moderate traumatic brain injury (TBI) to prevent the progression towards immunokine storms, systemic inflammatory response syndrome (SIRS), severe respiratory distress, and requirement for invasive mechanical ventilation, and death, when compared to SOC alone... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/02/2023
Locations: AHN Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Acute Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Traumatic Brain Injury
Register for Updates
Burst-Type Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
NCT05753449
Recruiting
This is a study to evaluate Deep brain stimulation (DBS) burst-type electrical stimulation programming verses standard DBS programming. Burst-type DBS is defined as a novel stimulation protocol in which intermittent bursts of traditional high-frequency rectangular wave stimulation are delivered. Burst type DBS may improve the efficacy and durability of DBS pulse generator.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/01/2023
Locations: AHN Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Parkinson Disease, Deep Brain Stimulation
Register for Updates
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
NCT05364645
Recruiting
This phase II Lung-MAP treatment trial tests whether carboplatin and pemetrexed with or without selpercatinib works to shrink tumors in patients with RET fusion-positive non-small cell lung cancer that is stage IV or has not responded to previous RET directed therapy. Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Selpercatinib may st... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: UPMC Altoona, Altoona, Pennsylvania
Conditions: Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model
NCT03934606
Recruiting
To evaluate an alternative clinical genetics cancer care delivery model, using non-genetic providers to introduce and order genetic testing. 250 prostate and 250 pancreatic patients will be recruiting. They will undergo genetic testing and complete study questionnaires. Results from this pilot study will be used to inform the strategies used by the Clinical Risk Evaluation Program (CREP) Genetic Counelors (CGS) and GI/GU physicians to deliver genetic testing and return genetic risk information t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: Penn Medicine - University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Pancreas Cancer, Prostate Cancer, Hereditary Cancer, Genetic Predisposition to Disease
Register for Updates